Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis
NCT00195507
Last updated date
ABOUT THIS STUDY
This study will provide a direct comparison of 'continuous therapy' and 'intermittent
therapy' with withdrawal and retreatment upon return of psoriasis.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Psoriasis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- Stable, active plaque psoriasis
- Failure to respond to the following systemic therapies: Methotrexate, Cyclosporine, PUVA or Fumarate
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Evidence of skin conditions other than psoriasis that would interfere with evaluations
of the effect of the study
- Systemic psoriasis therapy within 28 days prior
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
PsoriasisStudy Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept
NCT00992394
- Besancon,
- Limoges,
- Lyon Cedex 03,
- Nantes Cedex 01,
- Nice Cedex 03,
- Paris,
- Pierre Benite,
- Poitiers,
- Reims,
- Toulouse Cedex,
- Berlin,
- Bochum,
- Erlangen,
- Frankfurt am Main,
- Freiburg,
- Hamburg,
- Osnabrueck,
- Athens,
- Thessaloniki,
- Budapest,
- Debrecen,
- Miskolc,
- Szeged,
- Catania,
- Chieti,
- Parma,
- Santander, Cantabria
- Alcorcon, Madrid
- Getafe, Madrid
- Alicante,
- Madrid,
- Malaga,
- Istanbul, Capa
- Ankara, Etlik
- Ankara, Etlik
- Ankara, Etlik
- Istanbul, Fatih
- Bursa, Gorukle
- Pendik, Istanbul
- Ankara, Sihhiye
- Ankara, Sihhiye
- Ankara,
- Bornova / Izmir,
- Abu Dhabi, UAE
- Harrogate,
- London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
PsoriasisEffectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00678210
- Tucson, Arizona
- Little Rock, Arkansas
- Oceanside, California
- Jacksonville, Florida
- Miami, Florida
- West Dundee, Illinois
- Boston, Massachusetts
- Boston, Massachusetts
- Worcester, Massachusetts
- Saint Louis, Missouri
- East Windsor, New Jersey
- Paramus, New Jersey
- New York, New York
- Rochester, New York
- Winston Salem, North Carolina
- Cleveland, Ohio
- Norman, Oklahoma
- Lake Oswego, Oregon
- Portland, Oregon
- Portland, Oregon
- Philadelphia, Pennsylvania
- Greer, South Carolina
- Greer, South Carolina
- Mt. Pleasant, South Carolina
- Dallas, Texas
- Houston, Texas
- Webster, Texas
- Salt Lake City, Utah
- Norfolk, Virginia
- Vancouver, British Columbia
- Moncton, New Brunswick
- St. John's, Newfoundland and Labrador
- Halifax, Nova Scotia
- Halifax, Nova Scotia
- Halifax, Nova Scotia
- Barrie, Ontario
- London, Ontario
- North Bay, Ontario
- Waterloo, Ontario
- Windsor, Ontario
- Laval, Quebec
- Montreal, Quebec
- Montreal, Quebec
- Quebec,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
PsoriasisTopical CP-690,550 For Chronic Plaque Psoriasis
NCT00678561
- Irvine, California
- San Diego, California
- Chicago, Illinois
- Boston, Massachusetts
- Ann Arbor, Michigan
- Fridley, Minnesota
- Saint Louis, Missouri
- High Point, North Carolina
- WinstoN Salem, North Carolina
- Portland, Oregon
- Portland, Oregon
- Austin, Texas
- Salt Lake City, Utah
- Surrey, British Columbia
- St. John's, Newfoundland and Labrador
- Waterloo, Ontario
- Montreal, Quebec
- Montreal, Quebec
- Quebec,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
PsoriasisA One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
NCT01276639
- Birmingham, Alabama
- Irvine, California
- San Diego, California
- Santa Monica, California
- Denver, Colorado
- New Haven, Connecticut
- Ocala, Florida
- Tampa, Florida
- Alpharetta, Georgia
- Atlanta, Georgia
- Newnan, Georgia
- Springfield, Illinois
- Indianapolis, Indiana
- Boston, Massachusetts
- Boston, Massachusetts
- Omaha, Nebraska
- New York, New York
- Rochester, New York
- Raleigh, North Carolina
- Raleigh, North Carolina
- Norman, Oklahoma
- Lake Oswego, Oregon
- Pittsburgh, Pennsylvania
- Johnston, Rhode Island
- Knoxville, Tennessee
- Dallas, Texas
- Dallas, Texas
- Houston, Texas
- Spokane, Washington
- Spokane, Washington
- Wenatchee, Washington
- Madison, Wisconsin
- Winnipeg, Manitoba
- St. John's, Newfoundland and Labrador
- Halifax, Nova Scotia
- Barrie, Ontario
- Markham, Ontario
- North Bay, Ontario
- Oakville, Ontario
- Ottawa, Ontario
- Waterloo, Ontario
- Quebec,
- Barranquilla, Atlantico
- Bogot, Cundinamarca
- Berlin,
- Berlin,
- Bonn,
- Dresden,
- Hamburg,
- Kiel,
- Muenster,
- Schwerin,
- Vechta,
- Wuppertal,
- Kecskemet,
- Nyiregyhaza,
- Pecs,
- Maebashi-shi, Gunma
- Sapporo, Hokkaido
- Chuo-ku, Kobe
- Kumamoto-shi, Kumamoto
- Shinjyuku-ku, Tokyo
- Monterrey, Nuevo Leon
- Poznan,
- Szczecin,
- Wroclaw,
- Wroclaw,
- Belgrade,
- Tainan,
- Taipei,
- Simferopol, Crimea
- Kharkiv,
- Kyiv,
- Ternopil,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brief Title ICMJE | Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis | |||||||||||||||||||||||||||||||||
| Official Title ICMJE | A Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etanercept in the Treatment of Subjects With Psoriasis | |||||||||||||||||||||||||||||||||
| Brief Summary | This study will provide a direct comparison of 'continuous therapy' and 'intermittent therapy' with withdrawal and retreatment upon return of psoriasis. | |||||||||||||||||||||||||||||||||
| Detailed Description | Not Provided | |||||||||||||||||||||||||||||||||
| Study Type ICMJE | Interventional | |||||||||||||||||||||||||||||||||
| Study Phase ICMJE | Phase 4 | |||||||||||||||||||||||||||||||||
| Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||||||||||||||||||||||||||||||||
| Condition ICMJE | Psoriasis | |||||||||||||||||||||||||||||||||
| Intervention ICMJE | Drug: Etanercept | |||||||||||||||||||||||||||||||||
| Study Arms ICMJE | Not Provided | |||||||||||||||||||||||||||||||||
| Publications * |
| |||||||||||||||||||||||||||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||||||||||||||||||||||||||||||||
| Recruitment Information | ||||||||||||||||||||||||||||||||||
| Recruitment Status ICMJE | Completed | |||||||||||||||||||||||||||||||||
| Actual Enrollment ICMJE | 720 | |||||||||||||||||||||||||||||||||
| Original Enrollment ICMJE | 700 | |||||||||||||||||||||||||||||||||
| Actual Study Completion Date ICMJE | February 2007 | |||||||||||||||||||||||||||||||||
| Primary Completion Date | Not Provided | |||||||||||||||||||||||||||||||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||||||||||||||||||||||||||||||||
| Sex/Gender ICMJE |
| |||||||||||||||||||||||||||||||||
| Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||||||||||||||||||||||||||||||||
| Accepts Healthy Volunteers ICMJE | No | |||||||||||||||||||||||||||||||||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||||||||||||||||||||||||||||||||
| Listed Location Countries ICMJE | Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Netherlands, Norway, Poland, Portugal, Spain, Sweden, Switzerland, Turkey, United Kingdom | |||||||||||||||||||||||||||||||||
| Removed Location Countries | ||||||||||||||||||||||||||||||||||
| Administrative Information | ||||||||||||||||||||||||||||||||||
| NCT Number ICMJE | NCT00195507 | |||||||||||||||||||||||||||||||||
| Other Study ID Numbers ICMJE | 0881A6-101764 | |||||||||||||||||||||||||||||||||
| Has Data Monitoring Committee | Not Provided | |||||||||||||||||||||||||||||||||
| U.S. FDA-regulated Product | Not Provided | |||||||||||||||||||||||||||||||||
| IPD Sharing Statement ICMJE | Not Provided | |||||||||||||||||||||||||||||||||
| Responsible Party | Not Provided | |||||||||||||||||||||||||||||||||
| Study Sponsor ICMJE | Wyeth is now a wholly owned subsidiary of Pfizer | |||||||||||||||||||||||||||||||||
| Collaborators ICMJE | Not Provided | |||||||||||||||||||||||||||||||||
| Investigators ICMJE |
| |||||||||||||||||||||||||||||||||
| PRS Account | Wyeth is now a wholly owned subsidiary of Pfizer | |||||||||||||||||||||||||||||||||
| Verification Date | April 2010 | |||||||||||||||||||||||||||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | ||||||||||||||||||||||||||||||||||